Orfoxen 14.5 mg (Orforglipron)

Description

Orfoxen 14.5 mg (Orforglipron) is a prescription medicine product name supplied for this page. Before publishing or offering this exact brand, the manufacturer, product registration, active ingredient, and official packaging should be verified.

Orforglipron is an oral GLP-1 receptor agonist. In the United States, the FDA-approved product Foundayo contains orforglipron and is indicated with a reduced-calorie diet and increased physical activity for long-term weight management in eligible adults. The approved label includes a 14.5 mg tablet strength. This information applies to the verified Foundayo label, not automatically to Orfoxen.

This page explains what is known about orforglipron, how it works, its approved use, dosage principles, warnings, and important safety information. It also explains which product details customers should verify before considering a prescription medicine.

Orfoxen 14.5 mg should not be assumed to be interchangeable with another orforglipron brand. Ask a qualified prescriber or pharmacist to confirm the exact product. The FDA label for Foundayo lists oral tablets containing 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg of orforglipron. These are verified Foundayo label strengths, not proof of the available strengths or pack sizes of Orfoxen. 

Key Benefits of Orforglipron

Orforglipron is a medicine studied and approved for a specific weight-management use in eligible adults. It is not a general-purpose weight-loss product.

The approved Foundayo label describes its use alongside a reduced-calorie diet and increased physical activity. It is intended to help reduce excess body weight and maintain weight reduction over the long term in adults with obesity or adults with overweight and at least one weight-related medical condition.

Potential benefits depend on the individual, prescribed dose, treatment response, and ability to tolerate the medicine. Results should not be guaranteed.

Active Ingredient

The active ingredient identified for the supplied product is orforglipron.

Orforglipron is a small-molecule GLP-1 receptor agonist. It acts on GLP-1 receptors, which are involved in appetite regulation and glucose-related processes. The exact formulation, inactive ingredients, and strength of Orfoxen must be confirmed from its official product label.

How Orforglipron Works

Orforglipron activates GLP-1 receptors. These receptors are involved in the body’s regulation of appetite and blood glucose.

The approved label identifies orforglipron as a GLP-1 receptor agonist. Its mechanism is different from simply taking a dietary supplement or appetite-control product. It is a prescription medicine that requires appropriate clinical assessment.

Patients should not increase the dose to achieve faster results. The official label uses gradual dose escalation to help reduce gastrointestinal adverse reactions.

Indications and Uses

The verified Foundayo label states that orforglipron is indicated with a reduced-calorie diet and increased physical activity to:

• Reduce excess body weight in eligible adults with obesity.
• Reduce excess body weight in eligible adults with overweight and at least one weight-related comorbid condition.
• Maintain weight reduction over the long term.

These indications are based on the FDA-approved Foundayo label. They should not automatically be presented as approved uses for Orfoxen without confirming its own regulatory documentation.

Orforglipron should not be described as a treatment for every type of diabetes, obesity-related illness, or other condition unless the relevant product label specifically supports that use.

Dosage and Administration

What is the approved dosing approach?

The official Foundayo label starts treatment at 0.8 mg once daily. After at least 30 days, the dose may increase to 2.5 mg once daily. After at least 30 days at 2.5 mg, it may increase to 5.5 mg once daily. Further increases depend on treatment response and tolerability.

The approved label includes 9 mg, 14.5 mg, and 17.2 mg strengths for later dose levels. The maximum dose is 17.2 mg once daily.

The 14.5 mg strength is not a recommended starting dose. Do not start or change to this strength without instructions from your prescriber.

How to take the medicine

For the verified Foundayo product, the label states:

• Take orally once daily.
• Take with or without food.
• Swallow the tablet whole.
• Do not break, crush, or chew.
• Do not take more than one tablet per day.

These instructions should be confirmed against the official Orfoxen label before publishing them as product-specific instructions.

Missed dose

The Foundayo label states that a missed dose should be taken as soon as possible without doubling the next dose. If seven or more consecutive doses are missed, the label advises restarting dose escalation at a lower dose to reduce gastrointestinal adverse reactions.

Ask your prescriber or pharmacist how to manage a missed dose of the exact product you have.

Available Strengths

The following strengths are listed in the Foundayo label:

• 0.8 mg
• 2.5 mg
• 5.5 mg
• 9 mg
• 14.5 mg
• 17.2 mg

Orfoxen-specific strengths must be confirmed through its manufacturer or official product documentation. Do not use another brand’s strength list as proof of availability.

Available Pack Sizes

The official Foundayo label lists bottles of 30 tablets for the strengths described in its supply information.

The final product page should state the exact number of tablets, packaging format, batch details, and manufacturer information only after confirmation.

Who Can Use This Medicine?

Orforglipron is a prescription medicine for eligible adults under medical supervision.

A prescriber must determine whether treatment is appropriate based on medical history, current medicines, weight-related conditions, and possible risks.

The FDA-approved Foundayo indication concerns adults with obesity or adults with overweight and at least one weight-related comorbid condition.

This medicine should not be promoted for children or teenagers without an appropriate, product-specific indication and specialist medical guidance.

Who Should Not Use It?

The FDA-approved Foundayo label lists the following contraindications:

• A personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Known serious hypersensitivity to orforglipron or its excipients.

These contraindications must be checked against the official Orfoxen label.

Do not use prescription medicine based only on an online product description. A qualified clinician must determine suitability.

Warnings and Precautions

Thyroid C-cell tumor warning

The Foundayo label includes a boxed warning about the potential risk of thyroid C-cell tumors. The human relevance of the rodent findings is not determined. It contraindicates use in patients with a personal or family history of MTC or MEN 2.

Patients should discuss their personal and family history with their prescriber before treatment.

Pancreatitis

Acute pancreatitis has been observed with GLP-1 receptor agonists, including Foundayo. The label advises discontinuation if pancreatitis is suspected.

Seek urgent medical evaluation for severe or persistent abdominal pain, especially if it may be associated with vomiting.

Gastrointestinal reactions

Orforglipron may cause gastrointestinal adverse reactions. These can sometimes be severe. The Foundayo label does not recommend use in patients with severe gastroparesis.

Acute kidney injury

The label warns about acute kidney injury due to volume depletion. Renal function may need monitoring when adverse reactions cause fluid loss.

Hypoglycemia

Using orforglipron with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia.

Tell your prescriber about all diabetes medicines before starting treatment.

Possible Side Effects

The most common adverse reactions listed for Foundayo include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal discomfort

The exact frequency and severity depend on the dose and patient population.

The product label also includes warnings about serious gastrointestinal reactions, pancreatitis, kidney injury due to volume depletion, and hypersensitivity reactions.

This page should not present a complete adverse-reaction list as the official Orfoxen list until its own label is verified.

Drug Interactions

Orforglipron can interact with other medicines. The Foundayo label identifies specific concerns involving CYP3A4 inhibitors and inducers. Strong CYP3A4 inhibitors that also inhibit OATP1B should be avoided, and strong CYP3A4 inducers should be avoided. Dose modifications may be required with certain interacting medicines.

The label also includes information about oral hormonal contraceptives and dose escalation. Patients using oral hormonal contraceptives should follow the specific label guidance and discuss contraception with a qualified clinician.

Tell your pharmacist about:

• All prescription medicines.
• Over-the-counter medicines.
• Vitamins and supplements.
• Diabetes medicines.
• Medicines for other chronic conditions.

Do not stop or change any medicine without medical advice.

Storage Instructions

The correct storage conditions for Orfoxen 14.5 mg must be confirmed from its official packaging and label.

For the verified Foundayo product, the label describes bottles supplied with a desiccant and child-resistant closure.

Keep prescription medicines out of reach of children. Do not use tablets with damaged packaging, missing identification, or unclear expiry information.

Authenticity and Prescription Requirements

Orfoxen 14.5 mg is presented as a prescription product. The exact prescription and dispensing requirements depend on the product’s approved status and the applicable jurisdiction.

Customers should use a licensed pharmacy and follow the advice of a qualified prescriber.

The pharmacy should provide a clear process for verifying product identity, confirming prescriptions, and handling concerns about damaged or questionable packaging.

Conclusion

Orfoxen 14.5 mg (Orforglipron) is a product name that requires verified manufacturer and regulatory information before publication as a complete commercial medicine listing.

Orforglipron is an oral GLP-1 receptor agonist. The FDA-approved Foundayo label includes a 14.5 mg strength and describes its use for weight management in eligible adults alongside diet and physical activity.

The most important next step is to confirm the exact Orfoxen product label. Customers should review the approved use, dosage instructions, warnings, and interactions with a qualified healthcare professional before considering treatment.